(Q33726648)

English

A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study (English)

1 reference

Europe PubMed Central

28 July 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

Tohru Funahashi

13

object named as

Tohru Funahashi

1 reference

Europe PubMed Central

28 July 2017

author name string

Toshiyuki Hibuse

1

1 reference

Europe PubMed Central

28 July 2017

Norikazu Maeda

2

1 reference

Europe PubMed Central

28 July 2017

Ken Kishida

3

1 reference

Europe PubMed Central

28 July 2017

Takekazu Kimura

4

1 reference

Europe PubMed Central

28 July 2017

Tomoko Minami

5

1 reference

Europe PubMed Central

28 July 2017

Eriko Takeshita

6

1 reference

Europe PubMed Central

28 July 2017

Ayumu Hirata

7

1 reference

Europe PubMed Central

28 July 2017

Yasuhiko Nakagawa

8

1 reference

Europe PubMed Central

28 July 2017

Susumu Kashine

9

1 reference

Europe PubMed Central

28 July 2017

Akemi Oka

10

1 reference

Europe PubMed Central

28 July 2017

Masumi Hayashi

11

1 reference

Europe PubMed Central

28 July 2017

Hitoshi Nishizawa

12

1 reference

Europe PubMed Central

28 July 2017

Iichiro Shimomura

14

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

24 May 2014

1 reference

Europe PubMed Central

28 July 2017

Cardiovascular Diabetology

1 reference

Europe PubMed Central

28 July 2017

13

1 reference

Europe PubMed Central

28 July 2017

96

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1186/1475-2840-13-96

0 references

Adiponectin as a routine clinical biomarker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Incretin-based therapies: focus on effects beyond glycemic control alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Serum C1q- binding adiponectin in maintenance hemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Glucose lowering and cardiovascular disease: what do we know and what should we do?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Intensive glycemic control and cardiovascular disease: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Increased oxidative stress in obesity and its impact on metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

21 June 2018

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Adiponectin and development of type 2 diabetes in the Pima Indian population

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-13-96

21 January 2018

Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

30 October 2018

A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049487

30 October 2018

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/24884787

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/24884787

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1475-2840-13-96

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33726648&oldid=1970619798"